Key Points Dynavax Technologies (NASDAQ:DVAX) exceeded analyst expectations in Q2 2025, reporting GAAP revenue of $95.4 million and GAAP diluted EPS of $0.14. HEPLISAV-B, Dynavax's two-dose adult ...

The decision to cancel almost $500 million dollars in U.S. funding for the development of messenger RNA vaccines is dangerous ...

The project, which is eligible for tax breaks, will beef up economic development in San Marcos, the home of Texas State ...

The move drew sharp criticism from medical and health experts. “Scrapping the fastest platform we have is a reckless move ...

In statements to the USA TODAY Network, both the University of Rochester Medical Center, or URMC, and Regeneron noted they ...

Pfizer is the closest company to producing a Lyme disease vaccine. Experts are concerned that vaccine skepticism could stand in its way.

The Trump administration’s decision to terminate hundreds of millions of dollars to develop mRNA vaccines and treatments ...

Secretary Robert F. Kennedy Jr.’s decision this week to cancel hundreds of millions of dollars in mRNA vaccine funding will ...

HHS Secretary Robert F. Kennedy Jr. says the federal government is calling off around $500 million worth of vaccine ...

The Trump administration canceled about $500 million for research into mRNA vaccines. The move slows progress in using the ...

Robert F. Kennedy Jr halted 22 mRNA vaccine initiatives, drawing criticism from health experts over pandemic preparedness ...

The US Department of Health and Human Services (HHS) plans to cancel $500m (£376m) in funding for mRNA vaccines being ...